How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. - Alan, Ozkan; Kuzhan, Okan; Koca, Sinan; Telli, Tugba Akin; Basoglu, Tugba; Ercelep, Ozlem; Filinte, Deniz; Sengul, Yildiz; Arikan, Huseyin; Kaya, Serap; Babacan, Nalan Akgul; Dane, Faysal; et al. (Journal of Oncology Pharmacy Practice, 2020)